Michael Seiberling

2.0k total citations
45 papers, 1.6k citations indexed

About

Michael Seiberling is a scholar working on Epidemiology, Immunology and Molecular Biology. According to data from OpenAlex, Michael Seiberling has authored 45 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Epidemiology, 7 papers in Immunology and 6 papers in Molecular Biology. Recurrent topics in Michael Seiberling's work include Analytical Methods in Pharmaceuticals (5 papers), Chronic Myeloid Leukemia Treatments (5 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Michael Seiberling is often cited by papers focused on Analytical Methods in Pharmaceuticals (5 papers), Chronic Myeloid Leukemia Treatments (5 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Michael Seiberling collaborates with scholars based in Switzerland, United States and Germany. Michael Seiberling's co-authors include Bin Peng, Rolf Pokorny, Renaud Capdeville, Michael Hayes, Catherine Dutreix, Monique Ben‐Am, Felix Waldmeier, U Keller, Martine Hubert and James F. McLeod and has published in prestigious journals such as Journal of Allergy and Clinical Immunology, European Heart Journal and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Michael Seiberling

43 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Seiberling Switzerland 21 431 309 309 299 221 45 1.6k
Masahiko Kaito Japan 29 357 0.8× 539 1.7× 258 0.8× 1.5k 5.0× 242 1.1× 85 2.8k
John McCormick United States 21 225 0.5× 269 0.9× 120 0.4× 148 0.5× 195 0.9× 39 1.8k
Earl N. Metz United States 24 293 0.7× 503 1.6× 354 1.1× 198 0.7× 223 1.0× 43 1.8k
Hayato Miyachi Japan 25 289 0.7× 907 2.9× 92 0.3× 218 0.7× 467 2.1× 163 2.1k
Teresa Paglieroni United States 29 978 2.3× 346 1.1× 605 2.0× 264 0.9× 143 0.6× 60 2.8k
Amein K. Al‐Ali Saudi Arabia 23 413 1.0× 291 0.9× 458 1.5× 95 0.3× 71 0.3× 93 1.7k
Anne Hulin France 21 200 0.5× 321 1.0× 248 0.8× 224 0.7× 168 0.8× 74 1.4k
Ron J. Keizer Netherlands 20 129 0.3× 350 1.1× 98 0.3× 306 1.0× 364 1.6× 60 2.0k
Yi‐Lin Chiu United States 21 224 0.5× 1.0k 3.4× 268 0.9× 313 1.0× 452 2.0× 102 2.6k
Antonio Julià Spain 25 348 0.8× 780 2.5× 208 0.7× 180 0.6× 261 1.2× 73 2.1k

Countries citing papers authored by Michael Seiberling

Since Specialization
Citations

This map shows the geographic impact of Michael Seiberling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Seiberling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Seiberling more than expected).

Fields of papers citing papers by Michael Seiberling

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Seiberling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Seiberling. The network helps show where Michael Seiberling may publish in the future.

Co-authorship network of co-authors of Michael Seiberling

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Seiberling. A scholar is included among the top collaborators of Michael Seiberling based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Seiberling. Michael Seiberling is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Seiberling, Michael, et al.. (2013). Humoral immunity and delayed-type hypersensitivity in healthy subjects treated for 30days with MK-7123, a selective CXCR2 antagonist. International Immunopharmacology. 17(2). 178–183. 10 indexed citations
2.
Bruderer, Shirin, Gérard Hopfgartner, Michael Seiberling, et al.. (2012). Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans. Xenobiotica. 42(9). 901–910. 68 indexed citations
3.
Mueller, Edgar A., et al.. (2011). Pharmacokinetics and pharmacodynamics of calcium-vitamin D3chewable tablets: a single-blind, multiple-dose study in postmenopausal women. Expert Opinion on Drug Metabolism & Toxicology. 7(7). 785–791. 1 indexed citations
4.
Kovarik, John M., Alessandra Vitaliti, Frank Straube, et al.. (2010). Sotrastaurin and Tacrolimus Coadministration: Effects on Pharmacokinetics and Biomarker Responses. The Journal of Clinical Pharmacology. 50(11). 1260–1266. 10 indexed citations
5.
Kovarik, John M., Alessandra Vitaliti, Frank Straube, et al.. (2010). Sotrastaurin and cyclosporine drug interaction study in healthy subjects. Biopharmaceutics & Drug Disposition. 31(5-6). 331–339. 9 indexed citations
6.
Krishna, Gopal, Allen Moton, Lei Ma, et al.. (2009). Effects of Oral Posaconazole on the Pharmacokinetics of Atazanavir Alone and With Ritonavir or With Efavirenz in Healthy Adult Volunteers. JAIDS Journal of Acquired Immune Deficiency Syndromes. 51(4). 437–444. 23 indexed citations
7.
Tsai, Max, et al.. (2007). Evaluation of safety and pharmacokinetics of a fully human IGF-1 receptor antibody, SCH 717454, in healthy volunteers. Molecular Cancer Therapeutics. 6. 8 indexed citations
8.
9.
Seiberling, Michael, et al.. (2007). Assessment of the safety, tolerability, and PK/PD properties of two new formulations of subcutaneously administered IFN-?1a: a double-blind, placebo-controlled comparison with the currently available formulation. International Journal of Clinical Pharmacology and Therapeutics. 45(6). 307–318. 12 indexed citations
10.
Waldmeier, Felix, Ulrike Glaenzel, B. Wirz, et al.. (2007). Absorption, Distribution, Metabolism, and Elimination of the Direct Renin Inhibitor Aliskiren in Healthy Volunteers. Drug Metabolism and Disposition. 35(8). 1418–1428. 104 indexed citations
11.
Gschwind, Hans-Peter, Ulrike Pfaar, Felix Waldmeier, et al.. (2005). METABOLISM AND DISPOSITION OF IMATINIB MESYLATE IN HEALTHY VOLUNTEERS. Drug Metabolism and Disposition. 33(10). 1503–1512. 186 indexed citations
12.
Reyderman, Larisa, et al.. (2004). Pharmacokinetic interaction between ezetimibe and lovastatin in healthy volunteers*. Current Medical Research and Opinion. 20(9). 1493–1500. 13 indexed citations
13.
Nikolova, Zariana, Bin Peng, Martine Hubert, et al.. (2004). Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules. Cancer Chemotherapy and Pharmacology. 53(5). 433–438. 45 indexed citations
14.
Peng, Bin, Martine Hubert, Axel Krebs‐Brown, et al.. (2004). Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemotherapy and Pharmacology. 53(2). 102–106. 126 indexed citations
15.
Yates, R. A., J. Wong, Michael Seiberling, et al.. (2001). The effect of anastrozole on the single‐dose pharmacokinetics and anticoagulant activity of warfarin in healthy volunteers. British Journal of Clinical Pharmacology. 51(5). 429–435. 23 indexed citations
16.
Zhao, Jamie J., John Rogers, Sherry D. Holland, et al.. (1997). Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers. Biopharmaceutics & Drug Disposition. 18(9). 769–777. 76 indexed citations
17.
Hinderling, Peter H., et al.. (1995). Single‐Dose Interaction Study of Diprafenone HCl and Propranolol HCl in Healthy Volunteers. The Journal of Clinical Pharmacology. 35(7). 721–729.
18.
Skrumsager, Birte K., et al.. (1995). Tolerability, safety and pharmacokinetics of single dose and multiple dosing of the selective D1 antagonist NNC 01-0687 in healthy subjects. Psychopharmacology. 121(3). 294–299. 4 indexed citations
19.
Imbimbo, Bruno P., et al.. (1988). Safety and pharmacokinetics of mifentidine after increasing oral doses in healthy subjects. European Journal of Clinical Pharmacology. 35(6). 673–676. 1 indexed citations
20.
Seiberling, Michael, et al.. (1987). Clinical pharmacology of two specific bradycardic agents. European Heart Journal. 8(suppl L). 91–98. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Masahiko Kaito Breakdown of academic impact, for papers by John McCormick Breakdown of academic impact, for papers by Earl N. Metz Breakdown of academic impact, for papers by Hayato Miyachi Breakdown of academic impact, for papers by Teresa Paglieroni Breakdown of academic impact, for papers by Amein K. Al‐Ali Breakdown of academic impact, for papers by Anne Hulin Breakdown of academic impact, for papers by Ron J. Keizer Breakdown of academic impact, for papers by Yi‐Lin Chiu Breakdown of academic impact, for papers by Antonio Julià
Rankless by CCL
2026